Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | SVP, Regulatory & QA | February 13, 2025 | February 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date February 13, 2025 · Filed February 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2035-02-13 | Direct | 673,000 |
Reported balance
After 2025-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-13 · Grant · Acquired 673,000 · Balance 673,000 F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 448,660 |
Reported balance
After 2025-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-13 · Grant · Acquired 448,660 · Balance 448,660 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 18, 2025 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 448,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-005213 · form4.xml · derivative · entry 2 Corrigan Brian · CIK 0002032323 · SVP, Regulatory & QA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,660 Underlying: Common Stock · 448,660 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:18 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 673,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001127602-25-005213 · form4.xml · derivative · entry 1 Corrigan Brian · CIK 0002032323 · SVP, Regulatory & QA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,000 Underlying: Common Stock · 673,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 12:40 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001127602-24-021967 · form4.xml · derivative · entry 1 Corrigan Brian · CIK 0002032323 · SVP, Regulatory & QA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.